Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 42Thoracic 26Head & Neck 17Dermatologic 7Breast 7Other solid neoplasm 6Genitourinary 6Tumor-Agnostic 4Lymphoid 4Gynecologic 3CNS 3Sarcoma 2Other hematologic neoplasm 1

Conditions

Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Neoplasms 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

Cyclophosphamide 54Specimen Handling 50Magnetic Resonance Spectroscopy 49pembrolizumab 43Doxorubicin 43Radiotherapy 42Temozolomide 37Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Surgical Procedures, Operative 19Ifosfamide 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12Etoposide 12Blood Specimen Collection 12Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immune Checkpoint Inhibitors × Sarcoma × 1 year × Clear all
NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Baylor College of Medicine

Phase 1 Recruiting
25 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

BioAtla, Inc.

Phase 1/2 Completed
245 enrolled
Sarcoma

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡